Adenovirus Vaccines - PaxVax

Drug Profile

Adenovirus Vaccines - PaxVax

Alternative Names: Adenovirus Type 4 and Type 7 Vaccine [A549 Cells] - PaxVax; Modernized Production Adenovirus Vaccine - PaxVax; MPAV Prototype A; MPAV Prototype B; PXVX 0047

Latest Information Update: 30 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PaxVax
  • Developer PaxVax; Walter Reed Army Institute of Research
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Adenovirus infections

Most Recent Events

  • 08 May 2017 Preclinical trials in Adenovirus infections in USA (PO, Type 4 and 7 adenoviruses in a capsule)
  • 01 May 2017 Phase-I clinical trials in Adenovirus infections (In volunteers) in USA (PO, Type 4 and 7 adenoviruses in two separte capsule) (NCT03160339)
  • 21 Sep 2015 PaxVax receives phase II SBIR grant from United States Department of Defence for development of adenovirus type 4 and 7 vaccine in Adenovirus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top